Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Jubilant Life Sciences Ltd - 530019 - Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we certify that M/s Alankit Assignments Limited, a Category-I Registrar and Share Transfer Agent, registered with the Securities and Exchange Board of India vide Registration No.: INR000002532, is the Registrar and Share Transfer Agent (the 'RTA') of Jubilant Life Sciences Limited (the 'Company') and all activities in relation to both physical and electronic share transfer facility of the Company are being maintained by the RTA.
22-10-2019
Bigul

Jubilant Life Sciences Ltd - 530019 - Communication Pertaining To USFDA Approval

 We enclose a communication pertaining to USFDA approval. This is for your information and records.
22-10-2019
Bigul

Jubilant Life Sciences Ltd - 530019 - Partial Early Redemption Of 4.875% Senior Notes Due 2021 By Jubilant Pharma Limited, Wholly-Owned Subsidiary Of The Company (A Company Incorporated Under The Laws Of Singapore)

 Pursuant to Regulation 30 of the SEBI Listing Obligations, as amended, we wish to inform you that our material wholly-owned subsidiary, Jubilant Pharma Limited (''JPL'') has given notice to the holders of its US$300,000,000 4.875% Senior Notes due 2021 (the 'Notes') that it has elected to exercise its option to redeem US$100,000,000 in aggregate principal amount of the Notes on November 20, 2019 (the 'Redemption Date') pursuant to the terms of the indenture dated as of October 6, 2016 (the 'Indenture') between JPL and The Bank of New York Mellon, London Branch as trustee, governing the Notes. Pursuant to the terms of the Indenture, the redemption price for the Notes will be equal to 102.43750% of the principal amount of such Notes, plus accrued and unpaid interest thereon, to (but not including) the Redemption Date (the 'Redemption Price'). The Notes will be redeemed on a pro rata basis. This is for your information and records.
21-10-2019
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation of our letter dated October 17, 2019, we enclose copies of the advertisements published on October 18, 2019, in MINT (English) and HINDUSTAN (Hindi) with respect to notice of the Board Meeting scheduled to be held on October 25, 2019.
18-10-2019
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Shareholding for the Period Ended September 30, 2019

 Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here
18-10-2019
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Schedule Of Investor Conference Call For Jubilant Life Sciences Limited - Unaudited Financial Results For The Quarter Ended September 30, 2019

 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on October 25, 2019 after submission of the financial results for the quarter ended September 30, 2019 to the Stock Exchanges. Details of the Conference Call are attached.
17-10-2019
Bigul

Jubilant Life Sciences Ltd - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - October 25, 2019

 JUBILANT LIFE SCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2019 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, October 25, 2019, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended September 30, 2019.
17-10-2019
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Statement Of Investor Complaints For The Quarter Ended September 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- Rajiv ShahDesignation :- Company Secretary and Compliance Officer
16-10-2019
Bigul

Jubilant Life Sciences Ltd - 530019 - Announcement under Regulation 30 (LODR)-Credit Rating

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that India Ratings & Research has affirmed credit rating for various facilities of the Company as per the attached details. This is for your kind information and record.
16-10-2019
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of loss of share certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that share certificate has been reported to be lost by the shareholder as stated in the attached letter. The shareholder has requested for issuance of duplicate share certificate in lieu of the original. We propose to issue Duplicate Share Certificate to the shareholder on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record.
11-10-2019
Next Page
Close

Let's Open Free Demat Account